In a study investigating post-DRE urine samples from 154 patients undergoing prostate biopsies, biomarkers consisting of PSMA, PSGR, and PCA3 were used to distinguish between advanced versus indolent PCa, to then determine which patients should undergo biopsy. The gene discussed is FOLH1; the disease is posterior cortical atrophy.